Ceftazidime-avibactam activity against Escherichia coli and Klebsiella pneumoniae.

IF 1.7 Q4 MICROBIOLOGY

Iranian Journal of Microbiology Pub Date : 2025-02-01 DOI:10.18502/ijm.v17i1.17797

Arun Sachu, Alice David

{"title":"Ceftazidime-avibactam activity against Escherichia coli and Klebsiella pneumoniae.","authors":"Arun Sachu, Alice David","doi":"10.18502/ijm.v17i1.17797","DOIUrl":null,"url":null,"abstract":"Background and objectives: Carbapenem-resistant Enterobacteriaceae (CRE) infections are extremely difficult to treat and have a high fatality rate. The study's primary goal was to determine the rate of ceftazidime-avibactam susceptibility using disc diffusion and E-Test, as well as to evaluate the agreement between the two methods.Materials and methods: A total of 124 multidrug-resistant (including carbapenem) Escherichia coli and Klebisella pneumoniae isolates were included. Kirby Bauer's disc diffusion and E-test were used as the testing methods in this study.Results: In this study 37.5% and 33.9% of the isolates were susceptible to ceftazidime-avibactam by E test and Disc diffusion respectively. There were five isolates which produced discordant results. Among the 56 isolates there was 91% agreement between the two methods.Conclusion: Among the discordant isolates the alarming disparity in zone size was a significant concern. Since CRE infections are very common, an economical and practical method for testing ceftazidime-avibactam susceptibility is needed in all the clinical microbiology laboratories as it is a last resort drug.","PeriodicalId":14633,"journal":{"name":"Iranian Journal of Microbiology","volume":"17 1","pages":"19-24"},"PeriodicalIF":1.7000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12049754/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Microbiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/ijm.v17i1.17797","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and objectives: Carbapenem-resistant Enterobacteriaceae (CRE) infections are extremely difficult to treat and have a high fatality rate. The study's primary goal was to determine the rate of ceftazidime-avibactam susceptibility using disc diffusion and E-Test, as well as to evaluate the agreement between the two methods.

Materials and methods: A total of 124 multidrug-resistant (including carbapenem) Escherichia coli and Klebisella pneumoniae isolates were included. Kirby Bauer's disc diffusion and E-test were used as the testing methods in this study.

Results: In this study 37.5% and 33.9% of the isolates were susceptible to ceftazidime-avibactam by E test and Disc diffusion respectively. There were five isolates which produced discordant results. Among the 56 isolates there was 91% agreement between the two methods.

Conclusion: Among the discordant isolates the alarming disparity in zone size was a significant concern. Since CRE infections are very common, an economical and practical method for testing ceftazidime-avibactam susceptibility is needed in all the clinical microbiology laboratories as it is a last resort drug.

Abstract Image

查看原文本刊更多论文

头孢他啶-阿维巴坦抗大肠埃希菌和肺炎克雷伯菌活性。

背景和目的：碳青霉烯耐药肠杆菌科（CRE）感染极难治疗，死亡率高。本研究的主要目的是利用碟扩散法和E-Test法确定头孢他啶-阿维巴坦的药敏率，并评价两种方法的一致性。材料与方法：共纳入124株耐多药（含碳青霉烯类）大肠埃希菌和肺炎克雷比菌。本研究采用Kirby Bauer’s disc diffusion和E-test作为检验方法。结果：经E试验和Disc扩散试验，分离菌株对头孢他啶-阿维巴坦的敏感性分别为37.5%和33.9%。5个分离株结果不一致。在56株分离物中，两种方法的符合率为91%。结论：在不一致的隔离株中，隔离带大小的惊人差异值得关注。由于CRE感染非常常见，头孢他啶-阿维巴坦是最后一种药物，所有临床微生物实验室都需要一种经济实用的药敏检测方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Iranian Journal of Microbiology MICROBIOLOGY-

CiteScore

2.40

自引率

7.10%

发文量

审稿时长

12 weeks

期刊介绍： The Iranian Journal of Microbiology (IJM) is an international, multi-disciplinary, peer-reviewed journal that provides rapid publication of the most advanced scientific research in the areas of basic and applied research on bacteria and other micro-organisms, including bacteria, viruses, yeasts, fungi, microalgae, and protozoa concerning the development of tools for diagnosis and disease control, epidemiology, antimicrobial agents, clinical microbiology, immunology, Genetics, Genomics and Molecular Biology. Contributions may be in the form of original research papers, review articles, short communications, case reports, technical reports, and letters to the Editor. Research findings must be novel and the original data must be available for review by the Editors, if necessary. Studies that are preliminary, of weak originality or merely descriptive as well as negative results are not appropriate for the journal. Papers considered for publication must be unpublished work (except in an abstract form) that is not under consideration for publication anywhere else, and all co-authors should have agreed to the submission. Manuscripts should be written in English.